![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
2MB |
![[thumbnail of Supplementary Material]](https://edoc.mdc-berlin.de/style/images/fileicons/other.png) |
Other (Supplementary Material)
358kB |
| Item Type: | Article |
|---|---|
| Title: | Alectinib treatment improves photodynamic therapy in cancer cell lines of different origin |
| Creators Name: | Gillissen, B., Richter, A., Essmann, F. and Kemmner, W. |
| Abstract: | BACKGROUND: Photodynamic therapy with a photosensitizer such as protoporphyrin-IX, a light sensitive metabolite of heme synthesis, is a highly selective treatment for various carcinomas. In previous studies, we found a significant down regulation of the relevant enzyme ferrochelatase in gastrointestinal carcinomas leading to an accumulation of protoporphyrin-IX within the tumor cells. Recent studies showed that a novel anti-cancer drug, Alectinib, an orally available, highly selective, potent second-generation inhibitor of anaplastic lymphoma tyrosinkinase binds to ferrochelatase. Therefore, we were interested to see whether Alectinib treatment might lead to an accumulation of protoporphyrin IX. METHODS: Tumor cells of different origin were cultured, treated with LED-light and Alectinib. Results were gained by flow cytometry, immunohistochemistry and western blotting. Apoptosis was determined by flow cytometric analysis of Annexin V-FITC stained cells. In addition, cells were counterstained with propidium iodide to distinguish early apoptotic cells and late apoptotic/necrotic cells. RESULTS: Here, we report that photodynamic treatment of tumor cell lines of different origin in combination with Alectinib increased protoporphyrin-IX specific fluorescence and concomitantly cell death. CONCLUSIONS: The usage of Alectinib could be another step for enhancing the effectiveness of photodynamic therapy. Further experiments will show whether photodynamic therapy in combination with Alectinib could be a new strategy for the treatment of e.g. peritoneal disseminated carcinomas. |
| Keywords: | Photodynamic Therapy, Protoporphyrin-IX, Ferrochelatase, Alectinib, Gastrointestinal Carcinomas |
| Source: | BMC Cancer |
| ISSN: | 1471-2407 |
| Publisher: | BioMed Central |
| Volume: | 21 |
| Number: | 1 |
| Page Range: | 971 |
| Date: | 30 August 2021 |
| Official Publication: | https://doi.org/10.1186/s12885-021-08667-x |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
